Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raynaud's phenomenon.

J A Block1, W Sequeira

  • 1Section of Rheumatology, Rush Medical College, Rush-Presbyterian-St Luke's Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA. jblock@rush.edu

Lancet (London, England)
|July 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thirty years of publishing osteoarthritis research in perspective - a special journal issue to mark the 30th anniversary of Osteoarthritis and Cartilage.

Osteoarthritis and cartilage·2023
Same author

The Fundamentals of OA.

Osteoarthritis and cartilage·2021
Same author

The plain language summary (Lay Language Summary) in Osteoarthritis and Cartilage.

Osteoarthritis and cartilage·2021
Same author

The reproducibility crisis and statistical review of clinical and translational studies.

Osteoarthritis and cartilage·2021
Same author

Psychometric properties of MDHAQ/RAPID3 in patients with systemic lupus erythematosus.

Lupus·2018
Same author

Validation of the LupusPRO version 1.8: an update to a disease-specific patient-reported outcome tool for systemic lupus erythematosus.

Lupus·2017
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
See all related articles

Raynaud's phenomenon involves episodic vasospasm in fingers and toes triggered by cold. Understanding its vascular physiology and exploring new therapeutics like prostacyclin analogues offers hope for managing this condition.

Area of Science:

  • Vascular Physiology
  • Rheumatology

Background:

  • Raynaud's phenomenon presents as episodic vasospasm in the fingers and toes, often triggered by cold exposure.
  • While mild cases are common and not indicative of severe disability, the symptoms can be distressing.
  • A known association with systemic rheumatic conditions necessitates thorough diagnostic evaluations.

Purpose of the Study:

  • To review the clinical manifestations of Raynaud's phenomenon.
  • To explore recent advancements in understanding the pathophysiology of altered vasoregulation.
  • To discuss emerging therapeutic strategies targeting the underlying disease mechanisms.

Main Methods:

  • Literature review of clinical aspects of Raynaud's phenomenon.
  • Analysis of recent research on vascular physiology and vasoregulation in Raynaud's.

Related Experiment Videos

  • Synthesis of information on novel therapeutic targets and agents.

    • Main Results:

    • Advances in vascular physiology highlight the roles of both endothelial and endothelium-independent mechanisms in Raynaud's vasoregulation.
    • Established clinical features and associations are reviewed.
    • Potential therapeutic avenues are identified based on mechanistic insights.

    Conclusions:

    • Understanding the pathophysiology of Raynaud's phenomenon is crucial for developing effective treatments.
    • New therapeutic approaches targeting prostacyclin analogues, serotonin antagonists, and calcitonin gene-related peptides show promise.